REPAGLINIDE AND METFORMIN HYDROCHLORIDE (metformin hydrochloride; repaglinide) by Lupin Ltd. is 2 diabetes mellitus, lowering both basal and postprandial plasma glucose. First approved in 2015.
Drug data last refreshed 1h ago
2 diabetes mellitus, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. With metformin therapy, insulin secretion…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on REPAGLINIDE AND METFORMIN HYDROCHLORIDE at Lupin Ltd.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.